307 related articles for article (PubMed ID: 37884893)
21. p300 suppresses the transition of myelodysplastic syndromes to acute myeloid leukemia.
Man N; Mas G; Karl DL; Sun J; Liu F; Yang Q; Torres-Martin M; Itonaga H; Martinez C; Chen S; Xu Y; Duffort S; Hamard PJ; Chen C; Zucconi BE; Cimmino L; Yang FC; Xu M; Cole PA; Figueroa ME; Nimer SD
JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622806
[TBL] [Abstract][Full Text] [Related]
22. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
[No Abstract] [Full Text] [Related]
23. Bone marrow macrophages are involved in the ineffective hematopoiesis of myelodysplastic syndromes.
Xing T; Yao WL; Zhao HY; Wang J; Zhang YY; Lv M; Xu LP; Zhang XH; Huang XJ; Kong Y
J Cell Physiol; 2024 Feb; 239(2):e31129. PubMed ID: 38192063
[TBL] [Abstract][Full Text] [Related]
24. Bone marrow stromal cells from MDS and AML patients show increased adipogenic potential with reduced Delta-like-1 expression.
Weickert MT; Hecker JS; Buck MC; Schreck C; Rivière J; Schiemann M; Schallmoser K; Bassermann F; Strunk D; Oostendorp RAJ; Götze KS
Sci Rep; 2021 Mar; 11(1):5944. PubMed ID: 33723276
[TBL] [Abstract][Full Text] [Related]
25. Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression.
Cimmino L; Dolgalev I; Wang Y; Yoshimi A; Martin GH; Wang J; Ng V; Xia B; Witkowski MT; Mitchell-Flack M; Grillo I; Bakogianni S; Ndiaye-Lobry D; Martín MT; Guillamot M; Banh RS; Xu M; Figueroa ME; Dickins RA; Abdel-Wahab O; Park CY; Tsirigos A; Neel BG; Aifantis I
Cell; 2017 Sep; 170(6):1079-1095.e20. PubMed ID: 28823558
[TBL] [Abstract][Full Text] [Related]
26. U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity.
Badar T; Vanegas YAM; Nanaa A; Foran JM; Al-Kali A; Mangaonkar A; Murthy H; Alkhateeb HB; Viswanatha D; He R; Shah M; Yi CA; Litzow MR; Gangat N; Tefferi A; Patnaik MM
Blood Cancer J; 2023 Sep; 13(1):149. PubMed ID: 37735430
[TBL] [Abstract][Full Text] [Related]
27. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
[TBL] [Abstract][Full Text] [Related]
28. Aberrant DNA methylation impacts HOX genes expression in bone marrow mesenchymal stromal cells of myelodysplastic syndromes and de novo acute myeloid leukemia.
Roux B; Picou F; Debeissat C; Koubi M; Gallay N; Hirsch P; Ravalet N; Béné MC; Maigre M; Hunault M; Mosser J; Etcheverry A; Gyan E; Delhommeau F; Domenech J; Herault O
Cancer Gene Ther; 2022 Aug; 29(8-9):1263-1275. PubMed ID: 35194200
[TBL] [Abstract][Full Text] [Related]
29. Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms.
Greco M; D'Alò F; Scardocci A; Criscuolo M; Fabiani E; Guidi F; Di Ruscio A; Migliara G; Pagano L; Fianchi L; Chiusolo P; Hohaus S; Leone G; Voso MT
Blood Cells Mol Dis; 2010 Oct; 45(3):181-5. PubMed ID: 20655775
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders.
Kanavaros P; Stefanaki K; Rontogianni D; Darivianaki K; Vlychou M; Papadaki E; Eliopoulos G; Bakiri M; Matsouka C; Kakolyris S; Georgoulias V
Clin Exp Pathol; 1999; 47(5):231-8. PubMed ID: 10598372
[TBL] [Abstract][Full Text] [Related]
31. A zebrafish model of myelodysplastic syndrome produced through tet2 genomic editing.
Gjini E; Mansour MR; Sander JD; Moritz N; Nguyen AT; Kesarsing M; Gans E; He S; Chen S; Ko M; Kuang YY; Yang S; Zhou Y; Rodig S; Zon LI; Joung JK; Rao A; Look AT
Mol Cell Biol; 2015 Mar; 35(5):789-804. PubMed ID: 25512612
[TBL] [Abstract][Full Text] [Related]
32. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.
Ko M; Huang Y; Jankowska AM; Pape UJ; Tahiliani M; Bandukwala HS; An J; Lamperti ED; Koh KP; Ganetzky R; Liu XS; Aravind L; Agarwal S; Maciejewski JP; Rao A
Nature; 2010 Dec; 468(7325):839-43. PubMed ID: 21057493
[TBL] [Abstract][Full Text] [Related]
33. Evi-1 and MDS1-Evi-1 genes in pathogenesis of myelodysplastic syndromes and post-MDS acute myeloid leukemia.
Xu K; Wang L; Hao Y; Shao Z; Meng Q; Li K; Chao H; Tang K; Wang L
Chin Med J (Engl); 1999 Dec; 112(12):1112-8. PubMed ID: 11721451
[TBL] [Abstract][Full Text] [Related]
34. Mutation in TET2 in myeloid cancers.
Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA
N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426
[TBL] [Abstract][Full Text] [Related]
35. Secretion and Expression of Matrix Metalloproteinase-2 and 9 from Bone Marrow Mononuclear Cells in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Chaudhary AK; Chaudhary S; Ghosh K; Shanmukaiah C; Nadkarni AH
Asian Pac J Cancer Prev; 2016; 17(3):1519-29. PubMed ID: 27039800
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of Hmga2 activates Igf2bp2 and remodels transcriptional program of Tet2-deficient stem cells in myeloid transformation.
Bai J; Yokomizo-Nakano T; Kubota S; Sun Y; Kanai A; Iimori M; Harada H; Iwama A; Sashida G
Oncogene; 2021 Feb; 40(8):1531-1541. PubMed ID: 33452460
[TBL] [Abstract][Full Text] [Related]
37. CircZBTB46 predicts poor prognosis and promotes disease progression of myelodysplastic syndromes and acute myeloid leukemia.
Li S; Zhao G; Wu W; Li N; Wang Q; Wang W; Song X; Wang X
Clin Exp Med; 2023 Dec; 23(8):4649-4664. PubMed ID: 37930606
[TBL] [Abstract][Full Text] [Related]
38. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
Itzykson R; Kosmider O; Cluzeau T; Mansat-De Mas V; Dreyfus F; Beyne-Rauzy O; Quesnel B; Vey N; Gelsi-Boyer V; Raynaud S; Preudhomme C; Adès L; Fenaux P; Fontenay M;
Leukemia; 2011 Jul; 25(7):1147-52. PubMed ID: 21494260
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.
Cull AH; Mahendru D; Snetsinger B; Good D; Tyryshkin K; Chesney A; Ghorab Z; Reis M; Buckstein R; Wells RA; Rauh MJ
Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
